KP 136

03/01/1990 - "The pharmacological properties of KP-136, an inhibitor of type I allergy, were studied in rat paw models. "
03/01/1990 - "In four allergic responses, three of the immediate type and one delayed type, KP-136 (p.o.) produced potent inhibitions on the mast cell-mediated type I allergy (ID30: 1.0 mg/kg) and the neutrophil-infiltrated passive Arthus reaction (ID30: 1.6 mg/kg). "
04/01/1987 - "In four rat cutaneous reactions produced by three allergic reactions and compound 48/80, KP-136 was remarkably effective on two homologous PCA induced by IgE and IgGa. "

12/01/1988 - "KP-136 also inhibited A23187- and heat-induced degranulation and heat-induced hemolysis. "
03/01/1990 - "Although KP-136 was a weak inhibitor of carrageenin-induced paw edema, prostaglandin synthesis and complement-mediated hemolysis, the compound inhibited the release of lysosomal enzymes such as lysozyme and beta-glucuronidase in the passive Arthus reaction, suggesting the blockage of inflammatory mediator release for its mode of action."

03/01/1990 - "In addition, KP-136 (10 mg/kg, 50 mg/kg, p.o.) inhibited the injury of bone tissues in rat adjuvant arthritis, confirming that it was effective on the allergic inflammation with tissue injury. "

03/01/1990 - "[Effect of KP-136 on allergic paw edema in the rat]."
03/01/1990 - "Although KP-136 was a weak inhibitor of carrageenin-induced paw edema, prostaglandin synthesis and complement-mediated hemolysis, the compound inhibited the release of lysosomal enzymes such as lysozyme and beta-glucuronidase in the passive Arthus reaction, suggesting the blockage of inflammatory mediator release for its mode of action."

03/01/1989 - "KP-136 (1 mg/kg, i.v.) was also effective on allergic asthma of guinea pigs, although DSCG was ineffective even at a high dose of 50 mg/kg (i.v.). "
03/01/1989 - "KP-136 (0.125-1 mg/kg i.v., 0.5-2 mg/kg p.o.) produced a dose-dependent inhibition to allergic asthma of rats and was more potent than DSCG (1-5 mg/kg i.v.). "
03/01/1989 - "Effect of 8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-one [KP-136] on experimental asthma: a comparison with disodium cromoglycate."
03/01/1989 - "In rats, both KP-136 and DSCG significantly blocked the reduction of histamine content of the trachea after allergic asthma and inhibited the antigen-induced histamine release from lung fragments (KP-136 0.5 micrograms/ml, DSCG 50 micrograms/ml) and peritoneal exudate cells (KP-136 0.1 micrograms/ml, DSCG 10 micrograms/ml). "
03/01/1989 - "The pharmacological properties of 8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-one, KP-136 were compared with those of an antiallergic medicament, disodium cromoglycate (DSCG) in experimental asthma models. "